sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global D-Dimer Testing Market Size Study, by Test Type, by Application, by End-use and Regional Forecasts 2022-2032

Global D-Dimer Testing Market Size Study, by Test Type, by...

Home / Categories / Healthcare
Global D-Dimer Testing Market Size Study, by Test Type, by Application, by End-use and Regional Forecasts 2022-2032
Global D-Dimer Testing Market Size...
Report Code
RO1/103/2885

Publish Date
22/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The Global D-Dimer Testing Market is valued at approximately USD 1.37 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2024-2032. The D-Dimer test is a critical diagnostic tool used to detect the presence of blood clots in the body. It measures levels of D-Dimer, a protein fragment produced when a blood clot dissolves, helping healthcare professionals assess the risk of clot formation and manage conditions such as stroke and other thrombotic disorders. This test is pivotal in diagnosing and monitoring various conditions, including DVT, PE, and DIC, by providing valuable insights into the likelihood of clot formation and aiding in the timely intervention and effective management of these disorders.

The increasing prevalence of blood clotting disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC), is a significant factor driving market growth. The World Federation of Hemophilia reported that as of July 2022, 10,276 individuals with hemophilia were enrolled in 87 treatment centers across 40 countries. This highlights the growing need for effective diagnostic tools like the D-Dimer test. However, the market faces challenges such as a lack of standardization among D-Dimer assays and testing methodologies. This inconsistency can complicate the evaluation of patients and undermine the reliability of diagnostic conclusions. Furthermore, the emergence of aptamers as an alternative to antibodies for D-Dimer testing presents a significant shift in diagnostic methodologies. Aptamers offer cost-effective, stable, and rapidly produced solutions, enhancing the appeal of D-Dimer testing, particularly in resource-limited settings.

The D-Dimer testing market is segmented by test type, application, end-use, and region. The laboratory tests sub-segment dominated the market in 2022, reflecting their efficacy and reliability in providing accurate diagnostic insights. By application, the deep vein thrombosis (DVT) sub-segment was prominent, highlighting the critical role D-Dimer testing plays in diagnosing and managing DVT. The hospitals sub-segment led the market by end-use in 2022, emphasizing the central role hospitals play in diagnostic procedures and healthcare delivery.

The key regions considered for the Global D-Dimer Testing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Africa. In 2023, North America led the D-dimer testing market, underscoring the region's focus on proactive healthcare management. The widespread adoption of D-dimer testing across medical facilities has made it essential for evaluating thrombotic conditions and ruling out serious clotting disorders. This dominance highlights North America's commitment to advanced medical practices and a proactive approach to healthcare. The prevalence of D-dimer testing reflects the region's prioritization of early detection and intervention in thrombotic events, consistent with its broader healthcare ethos of preventative care. North America's significant share in the D-dimer testing market underscores its role as a leader in innovative medical technologies and diagnostic methodologies, setting a benchmark for other regions. On the other hand, Asia Pacific is poised to registered fastest growth over the forecast period 2024-2032.

Major market players included in this report are:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Siemens Healthineers
Abbott
Biomerieux SA
WERFEN
HORIBA, Ltd.
Quidel Corporation
Diazyme Laboratories, Inc.
Sekisui Diagnostics
LumiraDx Limited
Bio-Rad Laboratories
Danaher Corporation
Sysmex Corporation
Hologic, Inc.
The detailed segments and sub-segment of the market are explained below:
Test Type:
Point-of-Care Tests
Laboratory Tests
Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others
End-use:
Hospitals
Academic & Research Institutes
Diagnostic Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com